Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Other Non Operating Income (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Other Non Operating Income for 13 consecutive years, with -$579000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 5690.0% to -$579000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$518000.0 through Dec 2025, down 3137.5% year-over-year, with the annual reading at -$533000.0 for FY2025, 2861.11% down from the prior year.
  • Other Non Operating Income hit -$579000.0 in Q4 2025 for Guided Therapeutics, down from -$37000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $763000.0 in Q3 2021 to a low of -$579000.0 in Q4 2025.
  • Historically, Other Non Operating Income has averaged $9352.9 across 5 years, with a median of $1000.0 in 2022.
  • Biggest YoY gain for Other Non Operating Income was 9700.0% in 2025; the steepest drop was 5690.0% in 2025.
  • Year by year, Other Non Operating Income stood at $537000.0 in 2021, then crashed by 97.95% to $11000.0 in 2022, then plummeted by 372.73% to -$30000.0 in 2023, then soared by 66.67% to -$10000.0 in 2024, then plummeted by 5690.0% to -$579000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for GTHP at -$579000.0 in Q4 2025, -$37000.0 in Q3 2025, and $98000.0 in Q1 2025.